Table 3.

Overview of TEAEs and treatment discontinuations.

n (%)	Isa (N = 21)
Any TEAE (all grades)	21 (100)
Any grade ≥ 3 TEAE	10 (47.6)
Any serious TEAE	7 (33.3)
Any drug-related grade ≥ 3 TEAE	4 (19.0)
Any drug-related serious TEAE	2 (9.5)
Any grade 5 TEAE	4 (19)
Any TEAE leading to definitive treatment discontinuation	1 (4.8)
Any AESI (all grades)	0
Any IR (all grades)	13 (61.9)
Any IR grade ≥ 3	0

AESI, adverse event of special interest; IR, infusion reaction; Isa, isatuximab; TEAE, treatment-emergent adverse event.